A Phase I/IIa Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

Trial Profile

A Phase I/IIa Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Nivolumab (Primary) ; Pexastimogene devacirepvec (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Transgene
  • Most Recent Events

    • 31 Jul 2017 The principal investigator of this multi-center trial is Prof Olivier Rosmorduc, according to a Transgene media release.
    • 31 Jul 2017 The first patient has been treated in this trial, according to a Transgene media release.
    • 04 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top